Faculty of Health Sciences, American University of Science and Technology, Beirut 1100, Lebanon.
INSPECT-LB, Institut National de Santé Publique, Epidémiologie Clinique et Toxicologie, Beirut 1100, Lebanon.
Int J Environ Res Public Health. 2021 Jan 22;18(3):955. doi: 10.3390/ijerph18030955.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2. This review aims to describe the history, efficacy, and safety of five potential therapeutics for COVID-19, remdesivir, favipiravir, hydroxychloroquine, tocilizumab, and convalescent plasma. A literature review was conducted through October 2020 to identify published studies evaluating the efficacy and safety of these five potential therapeutics. Clinical improvement was used to assess the efficacy, while reported withdrawals from study participation and adverse events were used to evaluate the safety. In total, 95 clinical studies (6 interventional and 89 observational studies) were obtained, of which 42 were included in this review. The evaluation of the efficacy and safety profiles is challenging due to the limitations of the clinical studies on one hand, and the limited number of randomized controlled trials (RCTs) on the other. Moreover, there was insufficient evidence to support repurposing remdesivir, favipiravir, and tocilizumab for COVID-19.
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 大流行引起了严重的公共卫生关注，研究人员争分夺秒地寻找针对由 SARS-CoV-2 引起的 2019 年冠状病毒病 (COVID-19) 的有效且安全的治疗方法。本综述旨在描述五种有潜力的 COVID-19 治疗药物瑞德西韦、法匹拉韦、羟氯喹、托珠单抗和恢复期血浆的历史、疗效和安全性。通过 2020 年 10 月进行的文献回顾，确定了评估这五种有潜力的治疗药物疗效和安全性的已发表研究。临床改善用于评估疗效，而报告的研究参与退出和不良事件用于评估安全性。共获得 95 项临床研究（6 项干预性研究和 89 项观察性研究），其中 42 项研究被纳入本综述。由于临床研究的局限性以及随机对照试验 (RCT) 的数量有限，评估疗效和安全性概况具有挑战性。此外，瑞德西韦、法匹拉韦和托珠单抗用于 COVID-19 的重新定位证据不足。
Zotero 插件